Matrixx, H.I.G. Negotiated Deal For Nearly A Year, SEC Filings Show
This article was originally published in The Tan Sheet
Executive Summary
Records filed in connection with Matrixx Initiatives' pending sale to H.I.G. Capital show the deal was nearly a year in the making.
You may also be interested in...
Matrixx Bought By Private Equity Firm H.I.G., Settles Personal Injury Lawsuits
Matrixx Initiatives announced Dec. 14 private equity firm H.I.G. Capital will acquire the Scottsdale, Ariz.-based maker of Zicam cough/cold products for approximately $75.2 million.
Matrixx Misled Shareholders About Zicam Problems, Investors Allege
Shareholders in litigation against Matrixx Initiatives pending in the U.S. Supreme Court say a reasonable person's decision on whether information about a firm is important – not a statistical significance measure – should be the standard for determining when a company must reveal problems with a product.
Matrixx Trims Zicam Litigation Load To Focus on Personal Injury Claims
Matrixx Initiatives settles economic injury claims consumers filed about its Zicam nasal products, allowing the firm to focus on personal injury and shareholder litigation also linked to the products